[ad_1] Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. Eli Lilly & Co.’s shares climbed in early US trading after its experimental drug for Alzheimer’s slowed the progress of the disease in a final-stage trial, paving the way for the company to apply for US approval. …
Read More »Tag Archives: Biogen Inc
Healthy Returns: The launch of breakthrough Alzheimer’s drug Leqembi is off to a slow start
[ad_1] Good afternoon! The launch of the closely watched Alzheimer’s drug Leqembi is off to a slow start. Still, demand for the treatment from Biogen and its Japanese partner Eisai is rising. That’s the update the two drugmakers gave Wall Street during their latest quarterly earnings calls earlier this month. But …
Read More »What Eli Lilly investors can learn from the slow launch of a competitor’s drug
[ad_1] Club holding Eli Lilly is expecting to get approval for its Alzheimer’s treatment in the coming weeks, but investors looking for immediate financial success should temper their expectations. On its fourth-quarter earnings call Tuesday, rival drugmaker Biogen shared data that showed its therapy for the memory-robbing disease, Leqembi, is …
Read More »Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies
[ad_1] Biogen on Tuesday reported fourth-quarter revenue and profit that shrank from a year ago, as it recorded charges related to dropping its controversial Alzheimer’s drug Aduhelm and as sales slumped in its multiple sclerosis therapies, the company’s biggest drug category. Biogen booked sales of $2.39 billion for the quarter, down …
Read More »The S&P 500 will try to maintain its momentum next week after breaching 5,000, with key inflation data, earnings on deck
[ad_1] The S & P 500 broke past 5,000 for the first time ever this week, but investors will see if the momentum can stick in the week ahead with more inflation data and earnings results on deck. The 5,000 milestone does not represent technical resistance for the S & …
Read More »Biogen drops controversial Alzheimer’s drug Aduhelm to focus on Leqembi, experimental treatments
[ad_1] The Biogen headquarters in Cambridge, Massachusetts, on Oct. 24, 2023. Vanessa Leroy | Bloomberg | Getty Images Biogen on Wednesday said it will discontinue the sale and development of its older and highly controversial Alzheimer’s drug Aduhelm to refocus the company’s efforts to treat the memory-robbing disease. The biotech …
Read More »Why we like health-care stocks in 2024 despite their spotty record in presidential election years
[ad_1] As the old Wall Street adage goes, health care tends to underperform the stock market in presidential election years — and in recent cycles, that’s been true. But, there’s reason to believe this year that many health-related stocks, led by Eli Lilly , could defy historical convention. The S …
Read More »‘A trove of rebound opportunities’: Strategists turn bullish on biotech and more, picking top stocks
[ad_1] 2023 wasn’t a good year for the health-care sector, but some investors expect it to make a comeback this year — highlighting biotech and medical tech as areas to watch. “Emerging from a poor capital raising environment in ’22-23, where early-stage biotech companies grappled to fund their Research and …
Read More »Obesity and Alzheimer’s drugs pack one-two punch to power Eli Lilly higher in 2024
[ad_1] Investor optimism for Eli Lilly ‘s diabetes and obesity treatments in 2023 lifted the stock to its seventh annual gain in a row. In the new year, it should be the same old story. Shares of Eli Lilly have taken a breather over the past three months, as investors …
Read More »Weight loss drugs, Alzheimer’s treatments and gene editing: Enormous firsts defined 2023 in pharma
[ad_1] Soumyabrata Roy | Nurphoto | Getty Images Drugmakers are closing out a year when they achieved several historic firsts that will shape the pharmaceutical industry in 2024 and beyond. The weight loss drug market transformed into the pharmaceutical industry’s newest gold rush this year, as demand for costly but …
Read More »